Cowen analyst Eric Schmidt maintained an Outperform rating on Celgene Corporation (NASDAQ:CELG) with a price target of $110, which, surprisingly, represents a potential …
Cowen analyst Boris Peaker reiterated an Outperform rating on MEI Pharma (NASDAQ:MEIP), as the company reported clinical activity from a Phase II study of …
In a research report sent to investors, Cowen analyst Eric Schmidt maintained an Outperform rating on Sunesis Pharmaceuticals (NASDAQ:SNSS). No price target was provided.
Cowen analyst Eric Schmidt maintained an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO), as the company announced new data from its ongoing phase 1 trial …
Cowen analyst Boris Peaker maintained an Outperform rating on Celldex Therapeutics (NASDAQ:CLDX) with a price target of $26, following the news that the …
Cowen analyst Eric Schmidt maintained an Outperform rating on Incyte (NASDAQ:INCY), following the news that the company’s Jakafi gained FDA approval for the treatment …
In a research report sent to investors today, Cowen analyst Boris Peaker initiated coverage on Keryx Biopharmaceuticals (NASDAQ:KERX) with an Outperform rating and a $25 …
In a research report released Wednesday, Cowen analyst Eric Schmidt reiterated an Outperform rating on Puma Biotechnology (NYSE:PBYI), following the news that the company will …
In a research report sent to investors today, Cowen analyst Boris Peaker maintained an Outperform rating on Idera (NASDAQ:IDRA), while no price target …
Cowen analyst Eric Schmidt maintained an Outperform rating on Biogen Idec (NASDAQ:BIIB) with a price target of $389, after the company reported positive interim …
